Adaptive Biotechnologies Corp
corporate_fare Company Profile
Adaptive Biotechnologies Corp (NASDAQ:ADPT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for ADPT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for ADPT spans 10-Q, 4, 8-K, 144.
Recent high-impact activity:
- Adaptive 10-Q: Q3 Revenue $83.9M, Net Income $2.9M, Cash $400.2M
- Adaptive Biotechnologies Beats Q3 Revenue Estimates With $83.9M, Swings to Profit
- NCCN Guidelines Now Specifically Name clonoSEQ, Prefer 10^-6 MRD Sensitivity in Myeloma
- CEO Chad Robins Sells $14.9M in Stock After Exercising Options
- Adaptive Biotechnologies Beats Q2 Revenue, Lifts MRD Guidance, and Plans Business Separation
Financial Snapshot
Short Interest & Short Volume
6.07 days to coverFINRA reported short interest of 11,478,831 shares in ADPT as of the October 30, 2026 settlement, a 4.3% decrease from the prior period — about 6.1 days to cover at its recent average daily volume. On November 20, 2026, 40.6% of ADPT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ADPT, detected from its recent SEC filings · based on capital-structure filings through 2026-06-22.
Convertible Notes Issued · OrbiMed Debt Repaid
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →